Drug Trial Radar · NCT00412893
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
527
Actual
Start
Mar 7, 2007
Primary completion
Mar 28, 2013
Study completion Mar 28, 2013
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Basilea Pharmaceutica International Ltd
- First posted
- Dec 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
Conditions
- Aspergillosis
- Invasive Fungal Infection
Interventions
IsavuconazoleDrug
Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
VoriconazoleDrug
Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause Mortality Through Day 42Time frame: Through Day 42
Locations
107 sites in 26 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of California at San Francisco
San Francisco, California
University of Chicago, Division of Infectious Diseases
Chicago, Illinois
Indiana BMT
Springfield, Illinois
Springfield Clinic LLP
Springfield, Illinois
Infectious Disease of Indiana
Indianapolis, Indiana
Brigham & Womens Hospital
Boston, Massachusetts
Site not named
Worcester, Massachusetts
Upstate Infectious Diseases Association LLP
Albany, New York
Regional Infection Diseases Infusion Center Inc.
Lima, Ohio
University of Texas MD Anderson Cancer Center
Houston, Texas
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Capital Federal, Argentina
Site not named
Capital Federal, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma, Argentina
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma, Argentina
Site not named
Perth, Australia
Mater Medical Centre
South Brisbane, Australia
Site not named
Woolloongabba, Australia
AZ ST Jan
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
ULB Hospital Erasme
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Felicio Rocho
Belo Horizonte, Brazil
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, Brazil
Hospital das Clinicas da UFPR
Curitiba, Brazil
Hospital de Clinicas da FMUSP - Ribeirao Preto
Ribeirão Preto, Brazil
Hospital Universitario Clementino Fraga Filho
Rio de Janeiro, Brazil
Hamilton Health Sciences - Henderson Site
Hamilton, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
Site not named
Santiago, Chile
Hospital Dr. Hernan Henriquez Aravena
Temuco, Chile
Site not named
Valdivia, Chile
3rd Hospital, Peking University
Beijing, China
The 1st Hospital, Jilin University
Changchun, China
The Third Xiangya Hospital of Central South University
Changsha, China
West China Hospital of Sichuan University
Chengdu, China
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.